PATENT CLAIM ANALYSIS

Application Number: 16313956
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["546", "197000"]

Abstract:
Compounds of formula I, wherein R a  and R b  are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful as alpha2C antagonists.

Claim (Index 15):
The method according to  claim 14 , wherein the disorder, condition, or disease is a mental disorder propagated by stress, Parkinson's disease, depression, schizophrenia, attention deficit hyperactivity disorder, post-traumatic stress disorder, obsessive compulsive disorder, Tourette's syndrome, blepharospasm or other focal dystonias, temporal lobe epilepsy with psychosis, a drug-induced psychosis, Huntington's disease, a disorder caused by fluctuation of the levels of sex hormones, panic disorder, Alzheimer's disease, or mild cognitive impairment.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 98.0
- Lexical Diversity: 1.25
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12668918', '14192131', '13917745', '14747485', '14725683']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8072438100305496
- 35 USC 102 Novelty (BERT): 0.5274699729017105
- Combined Prediction Score: 0.7792664263176657
- Mean Citation Score: 313.98425400000013
- Max Citation Score: 358.68304
- Similarity Product: 306.1698850904465

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test